Literature DB >> 29979965

A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.

Eran Kotler1, Odem Shani2, Guy Goldfeld2, Maya Lotan-Pompan3, Ohad Tarcic2, Anat Gershoni2, Thomas A Hopf4, Debora S Marks4, Moshe Oren5, Eran Segal6.   

Abstract

The TP53 gene is frequently mutated in human cancer. Research has focused predominantly on six major "hotspot" codons, which account for only ∼30% of cancer-associated p53 mutations. To comprehensively characterize the consequences of the p53 mutation spectrum, we created a synthetically designed library and measured the functional impact of ∼10,000 DNA-binding domain (DBD) p53 variants in human cells in culture and in vivo. Our results highlight the differential outcome of distinct p53 mutations in human patients and elucidate the selective pressure driving p53 conservation throughout evolution. Furthermore, while loss of anti-proliferative functionality largely correlates with the occurrence of cancer-associated p53 mutations, we observe that selective gain-of-function may further favor particular mutants in vivo. Finally, when combined with additional acquired p53 mutations, seemingly neutral TP53 SNPs may modulate phenotypic outcome and, presumably, tumor progression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29979965     DOI: 10.1016/j.molcel.2018.06.012

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  58 in total

1.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

2.  Improved mutant function prediction via PACT: Protein Analysis and Classifier Toolkit.

Authors:  Justin R Klesmith; Benjamin J Hackel
Journal:  Bioinformatics       Date:  2019-08-15       Impact factor: 6.937

3.  New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.

Authors:  D Gareth Evans; Emma R Woodward
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

Review 4.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

5.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

Review 6.  Statin therapy: does sex matter?

Authors:  Stephanie S Faubion; Ekta Kapoor; Ann M Moyer; Howard N Hodis; Virginia M Miller
Journal:  Menopause       Date:  2019-12       Impact factor: 2.953

7.  Functional characterization of the p53 "mutome".

Authors:  Eran Kotler; Eran Segal; Moshe Oren
Journal:  Mol Cell Oncol       Date:  2018-09-25

8.  TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment.

Authors:  Martino Maddalena; Giuseppe Mallel; Nishanth Belugali Nataraj; Michal Shreberk-Shaked; Ori Hassin; Saptaparna Mukherjee; Sharathchandra Arandkar; Ron Rotkopf; Abby Kapsack; Giuseppina Lambiase; Bianca Pellegrino; Eyal Ben-Isaac; Ofra Golani; Yoseph Addadi; Emma Hajaj; Raya Eilam; Ravid Straussman; Yosef Yarden; Michal Lotem; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

9.  Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.

Authors:  Talayeh S Ghezelayagh; Kathryn P Pennington; Barbara M Norquist; Nithisha Khasnavis; Marc R Radke; Mark R Kilgore; Rochelle L Garcia; Ming Lee; Ronit Katz; Kimberly K Leslie; Rosa Ana Risques; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2020-12-26       Impact factor: 5.482

10.  PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.

Authors:  Basem Fares; Liron Berger; Einav Bangiev-Girsh; Reli Rachel Kakun; Dima Ghannam-Shahbari; Yuval Tabach; Yaniv Zohar; Eyal Gottlieb; Ruth Perets
Journal:  Oncogene       Date:  2021-07-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.